Related Experiment Videos
Dipyridamole first-pass radionuclide ventriculography: prediction of future cardiac events
R Bassevich1, N Zafrir, J Sulkes
1Department of Nuclear Medicine, Beilinson Medical Center, Petah Tiqwa, Israel.
Insights
Dipyridamole first-pass radionuclide ventriculography accurately predicts cardiac events in patients with coronary artery disease. This imaging technique offers significant prognostic value, serving as a viable alternative to dipyridamole thallium perfusion imaging for cardiac risk assessment.
Area of Science:
- Cardiology
- Nuclear Medicine
- Diagnostic Imaging
Background:
- Dipyridamole thallium imaging is established for assessing coronary artery disease.
- The prognostic utility of dipyridamole radionuclide ventriculography (DRV) was less understood.
- No prior long-term prognostic studies on DRV existed.
Purpose of the Study:
- To evaluate the prognostic value of dipyridamole first-pass radionuclide ventriculography (DPFRV) in predicting cardiac events.
- To assess the diagnostic accuracy of DPFRV in a large patient cohort.
Main Methods:
- 159 patients underwent DPFRV and were followed for cardiac events.
- Abnormal DPFRV response defined as wall motion reduction or ejection fraction decrease > 5 units.
- Correlation of imaging results with nonfatal myocardial infarction and cardiac death.
Main Results:
- An abnormal DPFRV response predicted increased risk of myocardial infarction (4.5% vs 0%) and cardiac death (9% vs 1%).
- DPFRV showed high sensitivity (86%), specificity (71%), and negative predictive value (98%) for future cardiac events.
- Relative risk for cardiac events was 15 (CI 12.06-18.1).
Conclusions:
- DPFRV demonstrated significant prognostic value in an unselected patient population.
- This technique is a useful and widely applicable alternative to dipyridamole thallium perfusion imaging.
- DPFRV aids in assessing cardiac risk for patients with coronary artery disease.
Abstract:
Dipyridamole thallium myocardial perfusion imaging is a useful alternative to stress testing in the diagnostic and prognostic assessment of patients with coronary artery disease. The diagnostic use of dipyridamole radionuclide ventriculography is much more controversial, but no long-term prognostic studies have been reported. Imaging results of 159 consecutive patients who were referred for dipyridamole first-pass radionuclide ventriculography were correlated with subsequent cardiac events over a mean follow-up period of 11 months. An abnormal response to dipyridamole infusion (any reduction in wall motion or absolute decrease in global left ventricular ejection fraction of > or = 5 ejection fraction units) was associated with an increased incidence of nonfatal myocardial infarction (4.5% vs 0%, p < 0.05) and cardiac-related death (9% vs 1%, p < 0.001). The sensitivity, specificity, and negative predictive value of dipyridamole first-pass radionuclide ventriculography in predicting future cardiac events were 86%, 71%, and 98%, respectively, with a relative risk of 15 (confidence interval 12.06 to 18.1). In conclusion, dipyridamole first-pass radionuclide ventriculography demonstrated significant prognostic value in a large unselected patient population. This technique may provide a widely applicable and useful alternative to dipyridamole thallium perfusion imaging in the assessment of cardiac risk in patients with coronary artery disease.